Rare diseases

News
Alnylam

Alnylam to file gene-silencing porphyria drug

Alnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying its gene silencing technology to the condition for the first time, following suppor

Views & Analysis
Harnessing RWE in rare diseases

Harnessing RWE in rare diseases

Ahead of eyeforpharma Philadelphia 2019, Sonal Bhatia, Pfizer’s vice president, North America medical lead, rare disease talked to us about the importance of collaboration and RWE to he

Partner Content
Banner for Media partners {460x250px}_3rd Aseptic Processing
Partner Content

3rd Annual Aseptic Processing Summit

Vonlanthen Group is pleased to invite you to the 3rd Annual Aseptic Processing Summit scheduled on November 20-21, in Vienna, Austria.